News
PRTG
0.2402
+1.35%
0.0032
12 Health Care Stocks Moving In Tuesday's Intraday Session
VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. Palisade Bio (NASDAQ:PALI) stock increased by 29.81% during the session. Kintara Therapeutics and NKGen Biotech were among the losers.
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 5d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Moolec Science stock is rocketing more than 67% on approval for its plant-groan animal proteins. Vaxxinity stock is crashing more than 55% on the company's plans to delist its shares. The biggest pre-market stock movers for Monday morning are earnings, investments, a delisting and more.
Investorplace · 6d ago
Weekly Report: what happened at PRTG last week (0415-0419)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. Kineta stock moved upwards by 16.62% and Erasca stock rose 13.73%. Nexalin Technology (NASDAQ:NXL) stock fell 18.4% during the day.
Benzinga · 04/19 12:08
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 04/18 20:31
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
The Travelers Companies, Inc. Shares dipped 8.1% to $205.03 on Wednesday. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. InVO Bioscience shares shot up 256% after the company reported a year-over-year increase in fourth-quarter revenue.
Benzinga · 04/17 17:36
12 Health Care Stocks Moving In Tuesday's Intraday Session
Palisade Bio (NASDAQ:PALI) stock increased by 65.1% to $6.87 during Tuesday's regular session. China SXT Pharmaceuticals and Intra-Cellular Therapies were among the gainers. Calidi Biotherapeutics (AMEX:CLDI) shares decreased by 58.5% during the session.
Benzinga · 04/16 16:31
Weekly Report: what happened at PRTG last week (0408-0412)?
Weekly Report · 04/15 10:45
Portage Biotech Explores Strategic Alternatives
TipRanks · 04/12 22:27
12 Health Care Stocks Moving In Friday's Intraday Session
PaxMedica stock increased by 110.9% to $0.87 during Friday's regular session. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% during the session. Cyclacel Pharmaceuticals shares increased by 20.45%. SenesTech and Motus GI Hldgs were among the losers.
Benzinga · 04/12 16:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. Allarity Therapeutics stock increased by 55.84% and HCW Biologics shares increased by 20.77%. Losers Motus GI Hldgs stock fell 26.1% during the session.
Benzinga · 04/12 12:09
Portage Biotech Announces Plans To Expand Its Evaluation Of Strategic Alternatives To Extend Its Available Cash Runway
Portage Biotech Inc. Is a clinical-stage immuno-oncology company. The company is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. The Board of Directors has paused further enrollment in the ADPORT-601 clinical trial.
Benzinga · 04/12 12:06
PORTAGE BIOTECH INC: IF COMPANY IS UNABLE TO COMPLETE A TRANSACTION, IT MAY BE REQUIRED TO SEEK A RESTRUCTURING OR COMPANY WIND DOWN
Reuters · 04/12 12:01
Portage Down on Announcing Alternatives
Portage Biotech Inc. Shares fall 2% to 49 cents. The company is expanding its evaluation of strategic alternatives. The Westport, Conn.-based company is a clinical-stage immuno-oncology concern. PRTG shares began Friday cheaper by a penny, or 2%.
Barchart · 04/12 08:43
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Portage Biotech Inc. Is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. The company is a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination.
Barchart · 04/12 07:01
Weekly Report: what happened at PRTG last week (0401-0405)?
Weekly Report · 04/08 10:49
Weekly Report: what happened at PRTG last week (0325-0329)?
Weekly Report · 04/01 10:47
Press Release: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway. Portage is a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination.
Dow Jones · 03/26 12:01
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Barchart · 03/26 07:01
More
Webull provides a variety of real-time PRTG stock news. You can receive the latest news about Portage Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRTG
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.